These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 27349646)

  • 1. Cost-effectiveness analysis of anal cancer screening in women with cervical neoplasia in British Columbia, Canada.
    Cromwell I; Gaudet M; Peacock SJ; Aquino-Parsons C
    BMC Health Serv Res; 2016 Jun; 16():206. PubMed ID: 27349646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of screening for anal squamous intraepithelial lesions and anal cancer in human immunodeficiency virus-negative homosexual and bisexual men.
    Goldie SJ; Kuntz KM; Weinstein MC; Freedberg KA; Palefsky JM
    Am J Med; 2000 Jun; 108(8):634-41. PubMed ID: 10856411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men.
    Goldie SJ; Kuntz KM; Weinstein MC; Freedberg KA; Welton ML; Palefsky JM
    JAMA; 1999 May; 281(19):1822-9. PubMed ID: 10340370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of screening for anal cancer using regular digital ano-rectal examinations in men who have sex with men living with HIV.
    Ong JJ; Fairley CK; Carroll S; Walker S; Chen M; Read T; Grulich A; Bradshaw C; Kaldor J; Clarke P
    J Int AIDS Soc; 2016; 19(1):20514. PubMed ID: 26942721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inefficiencies and High-Value Improvements in U.S. Cervical Cancer Screening Practice: A Cost-Effectiveness Analysis.
    Kim JJ; Campos NG; Sy S; Burger EA; Cuzick J; Castle PE; Hunt WC; Waxman A; Wheeler CM;
    Ann Intern Med; 2015 Oct; 163(8):589-97. PubMed ID: 26414147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of human papillomavirus-16/18 genotyping in cervical cancer screening.
    Huh WK; Williams E; Huang J; Bramley T; Poulios N
    Appl Health Econ Health Policy; 2015 Feb; 13(1):95-107. PubMed ID: 25385310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand.
    Blakely T; Kvizhinadze G; Karvonen T; Pearson AL; Smith M; Wilson N
    Vaccine; 2014 May; 32(22):2645-56. PubMed ID: 24662710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of annual versus biennial screening mammography for women with high mammographic breast density.
    Pataky R; Ismail Z; Coldman AJ; Elwood M; Gelmon K; Hedden L; Hislop G; Kan L; McCoy B; Olivotto IA; Peacock S
    J Med Screen; 2014 Dec; 21(4):180-8. PubMed ID: 25186116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost-effectiveness analysis of anal cancer screening in HIV-positive women.
    Lazenby GB; Unal ER; Andrews AL; Simpson K
    J Low Genit Tract Dis; 2012 Jul; 16(3):275-80. PubMed ID: 22227844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
    Demarteau N; Van Kriekinge G; Simon P
    Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness Analysis of Using Loss of Heterozygosity to Manage Premalignant Oral Dysplasia in British Columbia, Canada.
    Cromwell I; Regier DA; Peacock SJ; Poh CF
    Oncologist; 2016 Sep; 21(9):1099-106. PubMed ID: 27401887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of HPV vaccination alongside cervical cancer screening programme in Slovenia.
    Obradovic M; Mrhar A; Kos M
    Eur J Public Health; 2010 Aug; 20(4):415-21. PubMed ID: 20624834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada.
    Pataky R; Gulati R; Etzioni R; Black P; Chi KN; Coldman AJ; Pickles T; Tyldesley S; Peacock S
    Int J Cancer; 2014 Aug; 135(4):939-47. PubMed ID: 24443367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of strategies to increase cervical screening uptake at first invitation (STRATEGIC).
    Tsiachristas A; Gittins M; Kitchener H; Gray A
    J Med Screen; 2018 Jun; 25(2):99-109. PubMed ID: 28530515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.
    Kim JJ; Burger EA; Sy S; Campos NG
    J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27754955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling cost-effectiveness of cervical cancer screening in Hungary.
    Vokó Z; Nagyjánosi L; Margitai B; Kövi R; Tóth Z; László D; Kaló Z
    Value Health; 2012 Jan; 15(1):39-45. PubMed ID: 22264970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness of Screening and Treatment for Cervical Cancer in Tanzania: Implications for other Sub-Saharan African Countries.
    Nelson S; Kim J; Wilson FA; Soliman AS; Ngoma T; Kahesa C; Mwaiselage J
    Value Health Reg Issues; 2016 Sep; 10():1-6. PubMed ID: 27881270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
    Mittmann N; Au HJ; Tu D; O'Callaghan CJ; Isogai PK; Karapetis CS; Zalcberg JR; Evans WK; Moore MJ; Siddiqui J; Findlay B; Colwell B; Simes J; Gibbs P; Links M; Tebbutt NC; Jonker DJ; ;
    J Natl Cancer Inst; 2009 Sep; 101(17):1182-92. PubMed ID: 19666851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incremental cost-effectiveness of the pre- and post-bevacizumab eras of metastatic colorectal cancer therapy in British Columbia, Canada.
    Hedden L; Kennecke H; Villa D; Johnston K; Speers C; Kovacic L; Renouf DJ; Peacock S
    Eur J Cancer; 2012 Sep; 48(13):1969-76. PubMed ID: 22325838
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.